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EXPERIMENTAL STUDIES
Local Delivery of 17-Beta-Estradiol
Decreases Neointimal Hyperplasia
After Coronary Angioplasty in a Porcine Model
Baskaran Chandrasekar, MD, Jean-François Tanguay, MD
Montreal, Quebec, Canada
BACKGROUND Neointimal hyperplasia is an important mechanism of restenosis after percutaneous translu-
minal coronary angioplasty (PTCA). Systemically administered estrogen is known to inhibit
neointimal formation after arterial injury.
OBJECTIVES We sought to assess the efficacy of locally delivered 17-beta-estradiol (BE) in inhibiting
neointimal hyperplasia after PTCA.
METHODS Eighteen juvenile farm pigs were studied. Coronary angioplasty was performed in all three
coronary arteries of each animal. After PTCA, each coronary artery in each pig was
randomized to receive either local delivery of 600 mg BE, vehicle alone or PTCA only.
Twelve animals were euthanized at 28 days for morphometric analysis, and four animals were
euthanized at seven days for immunohistochemical analysis of vascular smooth muscle cell
(SMC) proliferative activity. Two animals died a few days after PTCA and were excluded.
RESULTS On morphometric study, the arterial segments treated with BE demonstrated significantly
less neointimal proliferation. Arteries treated with BE had reductions in several indexes of
restenosis compared with arteries treated with vehicle alone or PTCA only: neointimal area
(0.4 6 0.09 mm2 for BE vs. 1.14 6 0.33 mm2 for vehicle alone vs. 0.88 6 0.2 mm2 for PTCA
only, p , 0.05), percent neointima (12.16 6 2.57% vs. 25.46 6 4.73% vs. 23.02 6 3.97%,
p , 0.025), neointima/media area (0.59 6 0.14 vs. 1.75 6 0.41 vs. 1.67 6 0.43, p , 0.01)
and restenotic index (1.3 6 0.14 vs. 2.42 6 0.22 vs. 2.4 6 0.23, p , 0.005). Immunohis-
tochemistry showed decreased SMC proliferative activity in BE-treated arteries compared
with the other two treatment groups (p , 0.05).
CONCLUSIONS Local delivery of BE significantly decreases neointimal hyperplasia after PTCA in pigs,
probably by the inhibition of SMC proliferation. (J Am Coll Cardiol 2000;36:1972–8) ©
2000 by the American College of Cardiology
Restenosis is currently the major limitation of percutaneous
transluminal coronary angioplasty (PTCA), as seen in up to
30% to 40% of patients. Neointimal proliferation is a
fundamental mechanism of restenosis. Although brachy-
therapy has been reported to show beneficial effects (1,2), no
effective therapy exists yet for neointimal proliferation.
Vascular smooth muscle cell (SMC) migration and prolif-
eration occur as early as 36 h after arterial injury (3). In cell
culture assays, 17-beta-estradiol (BE) inhibited the migra-
tion and proliferation of rat vascular SMCs (4,5). Similar
effects have also been shown with human vascular SMCs
from the saphenous vein (6). Prolonged systemic adminis-
tration of estrogen has been shown to inhibit intimal
hyperplasia in animal studies (7,8). In the present experi-
ment, we tested the hypothesis that local administration of
BE during PTCA could effectively inhibit neointimal pro-
liferation.
METHODS
Animal preparation. Eighteen juvenile farm pigs (nine
sexually immature females with intact ovaries and nine
castrated males), approximately three months old and
weighing 20 to 25 kg, were studied. The males were
castrated at birth. The animals were fed regular pig chow in
which the bulk of protein was derived from a nonsoybean
source, as soybean contains significant amounts of phy-
toestrogens, which could potentially influence the effect of
BE. The study was approved by and conducted in accor-
dance with the guidelines of the Animal Care and Ethical
Research Committee of the Montreal Heart Institute.
Before the procedure, animals were given 650 mg of
acetylsalicylic acid and 30 mg of nifedipine orally, premed-
icated with an intramuscular injection of 6 mg/kg body
weight of a mixture of tiletamine hydrochloride and zolaz-
epam hydrochloride and given 0.5 mg of atropine. The
invasive procedure was performed under general anesthesia
with a mixture of isoflurane (1% to 1.5%) and oxygen-
enriched air. The right femoral artery was cannulated
percutaneously, and an 8F arterial sheath was introduced.
After arterial access had been obtained, 100 mg of lidocaine
and 250 U/kg of heparin were administered intra-arterially
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through the sheath. The activated coagulation time was
maintained at .300 s throughout the procedure.
Angioplasty and local delivery. Standard PTCA equip-
ment was used. An 8F right Amplatz guiding catheter and
right Judkin’s guiding catheter were used for cannulation of
the left and right coronary arteries, respectively. Heart rate,
blood pressure and the electrocardiogram were monitored
throughout the experiment. Coronary angioplasty was per-
formed with a balloon size chosen to correspond to a
balloon/artery ratio of 1.1:1.2. Three 30-s inflations at
10 atm were performed with a 30-s interval between
inflations. All three coronary arteries of each animal were
subjected to PTCA. After PTCA, each animal’s coronary
artery was randomized to receive either 600 mg BE locally,
vehicle alone locally or PTCA only. The chemicals BE and
its vehicle 2-hydroxypropyl-beta-cyclodextrin (HPCD)
were purchased from Sigma Chemicals. The InfusaSleeve
catheter (LocalMed, Inc., Palo Alto, California) was used
for local delivery (9). Five milliliters of the designated
substance was delivered at a driving pressure of 10 atm and
support balloon pressure of 6 atm. The dose of BE
(;30 mg/kg body weight) was chosen as representative of a
daily dose of systemic BE therapy used in previous studies,
which ranges from 10 to 100 mg/kg.
Of the 18 animals, two died a few days after PTCA and
were excluded; thus, 16 animals were analyzed. Twelve
animals were euthanized at 28 days and four at 7 days. After
premedication and anesthesia, the right internal jugular vein
and common carotid artery were cannulated. After cross-
clamping of the descending thoracic aorta through a left
lateral thoracotomy, exsanguination was performed, with
simultaneous administration of 1 liter of 0.9% sodium
chloride solution. The heart was perfusion-fixed in vivo
with 2 liter of 10% buffered formalin at 200 mm Hg,
removed from the animal and placed in 10% buffered
formalin solution. The site of PTCA was identified in
relation to adjacent side branches, which served as land-
marks. The injured segment was harvested with a 1-cm
normal segment proximal and distal to the injured site.
Serial sections 3 to 5 mm long were made from the
harvested segment, with a minimum of at least three
sections (maximum of 5) from each PTCA site. The
sections were stored in buffered 10% formalin and dehy-
drated with increasing concentrations of alcohol, followed
by treatment with xylene and paraffin. Each section was cut
into 6-mm-thick slices with a microtome (Olympus cut
4060 E) and stained with Verhoeff’s stain for morphometric
analysis.
Morphometric analysis. Measurements were made with a
video microscope linked to a 486 personal computer and
customized software. A minimum of three sections for each
injured segment were analyzed, and the results were aver-
aged. When individual values were widely discrepant for an
injured segment (observed in only one injured vessel), all
sections demonstrating rupture of the internal elastic lamina
(IEL) were included for analysis. Analyses were performed
by an examiner who had no knowledge of the treatment
assignment of the injured segments. The areas of external
elastic lamina (EEL), IEL and lumen were measured by
digital planimetry; neointimal area (IEL 2 lumen area) and
medial area (EEL 2 IEL area) were obtained. The fracture
length (FL) was measured as the length of discontinuity of
the injured IEL, and measurement of the extent of injury
was controlled by standardization for each artery, expressed
in relation to the circumference of the IEL (10,11). The
extent of injury was determined by the ratio of FL to IEL
circumference (FL/IEL). The percent neointima was de-
fined as the percent total vessel area occupied by the
neointima ([intimal area/EEL] 3 100). Morphologic per-
cent stenosis was calculated as 100 (1 2 lumen/IEL area)
(10). The restenotic index was defined as [intimal area/
(intimal area 1 medial area)]/(FL/IEL circumference) (11).
Injury score was determined as previously defined (12).
Immunohistochemistry. After slicing with a microtome
and blocking of nonspecific antibodies, the sections were
treated with mouse anti–proliferating cell nuclear antigen
(PCNA) antibodies and diluted biotinylated goat antimouse
antibodies. They were incubated with avidin-biotin (Elite
ABC Kit, Vector Laboratories, Burlingame, California),
developed with 3,39-diaminobenzidine (Vector Laborato-
ries) and counterstained with hematoxylin. Porcine liver
cells served as the positive control. For each section, a 6-mm
slice counterstained with hematoxylin without treatment
with the primary antibody (mouse anti-PCNA) served as
the negative control.
Immunohistochemistry was performed on samples from
animals euthanized at seven days. The percentage of pro-
liferating SMCs was obtained by dividing the number of
PCNA-positive SMCs by the total number of SMCs in
each field; separate measurements were made for neointimal
and medial layers. To standardize comparison among treat-
ment groups, measurements were obtained at four fixed
locations separated by 90° for each section, and the results
were averaged. For each segment, two sections demonstrat-
ing a maximal neointimal response were analyzed, and the
results averaged.
Statistical analysis. Values are expressed as the mean
value 6 SEM. Kruskal-Wallis analysis was used for com-
parison of data among the three groups. Multiple compar-
isons between the BE and PTCA-only groups and between
the vehicle-only and PTCA-only groups were made using
Abbreviations and Acronyms
BE 5 17-beta-estradiol
EEL 5 external elastic lamina
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the Student-Newman-Keuls test. Chi-square analysis was
used for comparison of proportions. Values were considered
significant at p , 0.05.
RESULTS
After PTCA and local delivery, the animals were allowed to
recover and gained weight steadily. Two animals died 48
and 72 h, respectively, after the procedure and were ex-
cluded; thus, 16 animals were studied. Autopsy of the two
animals revealed occlusive thrombus at the site of PTCA (in
the BE-treated vessel in one pig and in the vessel treated
with PTCA only in the other pig).
No changes in heart rate, electrocardiographic variables
or blood pressure were observed during local delivery.
Injured segments. The balloon/artery ratio and artery
diameter were similar among the three treatment groups
(Table 1). Segments with intact IEL in which discernible
injury was absent were excluded from analysis (two from the
PTCA-only group and one from the vehicle-only group).
Two segments were lost during harvesting (one from the
vehicle-only group and one from the PTCA-only group).
Morphometric analysis. On morphometric analysis at 28
days, arterial segments treated with local delivery of BE
showed significantly less neointimal hyperplasia compared
with the other two treatment groups (Fig. 1). This beneficial
effect was noted in all of the variables of neointimal response
to injury analyzed (Table 1). The extent of injury was similar
among the three groups, suggesting that the use of the
InfusaSleeve catheter was not associated with enhanced risk
of injury. The noninjured segments proximal and distal to
the sites of PTCA appeared morphologically normal, with
no evidence of inflammation or necrosis.
To exclude the existence of an inhibitory effect on intimal
proliferation due to the vehicle, analyses were performed
comparing segments treated with vehicle alone and PTCA
only, which showed no significant differences. In contrast,
significantly less intimal hyperplasia was observed in BE-
treated segments as compared with segments treated with
PTCA only (Fig. 2). Compared with PTCA only or vehicle
alone, BE decreased neointimal formation by ;50%.
The existence of a significant protective effect of BE as
compared with placebo or vehicle treatment by gender was
then assessed (Table 2 and 3). Although the extent of injury
in the BE-treated segments appeared slightly greater in
males and slightly less in females, compared with the other
two treatment groups, they were not statistically significant.
A significant protective effect of BE on the neointimal
response to injury was demonstrated in both genders.
There were no significant differences in the effect of BE
in the different arteries treated (left anterior descending vs.
Figure 1. Representative light micrographs (340) of arterial segments from the three treatment groups: (A) BE-treated artery (extent of injury 5 0.23,
neointimal area 5 0.24 mm2); (B) PTCA only–treated artery (extent of injury 5 0.29, neointimal area 5 1.00 mm2); and (C) vehicle only–treated artery
(extent of injury 5 0.23, neointimal area 5 1.3 mm2).
Table 1. Morphometric Analysis
Characteristics BE
PTCA
Only
Vehicle
Alone p Value
Segments analyzed (n) 12 9 10 NS
Artery size (mm) 2.86 6 0.1 2.94 6 0.08 2.94 6 0.13 NS
Balloon/artery ratio 1.22 6 0.03 1.2 6 0.02 1.17 6 0.03 NS
EELref/EELinj* 1.01 6 0.05 1.16 6 0.11 1.31 6 0.15 NS
Fracture length (mm) 1.64 6 0.27 1.71 6 0.25 1.81 6 0.25 NS
Extent of injury 0.25 6 0.04 0.25 6 0.04 0.25 6 0.04 NS
Neointimal area (mm2) 0.40 6 0.09 0.88 6 0.20 1.14 6 0.33 ,0.05
Neointimal area/fracture length (mm2) 0.25 6 0.04 0.5 6 0.07 0.58 6 0.13 ,0.005
Percent neointima 12.16 6 2.57 23.02 6 3.97 25.46 6 4.73 ,0.025
Neointima/media area 0.59 6 0.14 1.67 6 0.43 1.75 6 0.41 ,0.01
Percent stenosis 15.67 6 3.22 27.51 6 4.39 30.34 6 5.40 ,0.025
Restenotic index 1.3 6 0.14 2.4 6 0.23 2.42 6 0.22 ,0.005
Injury score 1.64 6 0.1 1.7 6 0.14 1.77 6 0.15 NS
*EELref 5 proximal reference segment external elastic lamina area; EELinj 5 injured segment external elastic lamina area
(averaged). Data are presented as the mean value 6 SEM.
BE 5 17-beta-estradiol; NS 5 not significant.
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circumflex vs. right coronary artery). Neointimal area
(0.28 6 0.16 vs. 0.47 6 0.16 vs. 0.46 6 0.15 mm2, p 5
NS), neointimal area/FL (0.17 6 0.04 vs. 0.35 6 0.11 vs.
0.25 6 0.06, p 5 NS) and restenotic index (1.2 6 0.14 vs.
1.72 6 0.27 vs. 1.12 6 0.25, p 5 NS) were similar in the
different arteries treated with BE.
Immunohistochemistry. A statistically significant decrease
in proliferating SMCs (PCNA-positive SMCs) was seen in
the arterial segments treated with BE. Among the different
groups, the percentage of PCNA-positive SMCs in the
neointima were 0.43 6 0.26% with BE, 4.26 6 1.17% with
PTCA only and 4.27 6 1.37% with vehicle alone (p , 0.05
for BE vs. other two groups). There were no significant
differences in the percentage of PCNA-positive SMCs in
the media between the three groups: 0.4 6 0.15%, 1.38 6
0.87% and 1.24 6 0.79% for BE, PTCA only and vehicle
alone, respectively (p 5 NS).
Vascular remodeling. To determine the effect on vascular
remodeling of the agents used, the EEL areas of the injured
segment and of the normal vessel proximal to the PTCA
site were obtained, and their ratio calculated (10). No
significant difference between the groups was noted: 1.01 6
0.05, 1.16 6 0.11 and 1.31 6 0.15, respectively, for BE,
PTCA only and vehicle alone (p 5 NS).
DISCUSSION
The present study demonstrates, for the first time, to our
knowledge, that locally delivered BE decreases neointimal
proliferation after PTCA in pigs. The study also shows that
Figure 2. Comparison of (A) neointimal area (NI); (B) neointimal/media area (NI/M); (C) restenotic index; and (D) neointimal area/fracture length (NI/F)
between PTCA-only and BE-treated groups, and between PTCA only and vehicle-only groups. *p 5 NS. **p , 0.05.
Table 2. Morphometric Data in Male Pigs
Characteristics BE
PTCA
Only
Vehicle
Alone p Value
Extent of injury 0.32 6 0.05 0.26 6 0.04 0.26 6 0.04 NS
Neointimal area (mm2) 0.51 6 0.13 1.01 6 0.29 0.99 6 0.23 NS
Neointima area/fracture length (mm2) 0.25 6 0.06 0.52 6 0.09 0.5 6 0.08 ,0.025
Neointima area/media area 0.78 6 0.21 2.05 6 0.69 1.65 6 0.4 0.05
Restenotic index 1.24 6 0.21 1.84 6 0.27 1.92 6 0.31 ,0.025
Data are presented as the mean value 6 SEM.
Abbreviations as in Table 1.
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local delivery of BE can be performed safely using the
InfusaSleeve catheter, without significant additional injury.
Local delivery and injury response. Systemic administra-
tion of pharmacologic agents may not achieve a local
concentration of the agent to produce a significant effect; in
addition, higher doses may result in intolerance or toxicity.
Unlike systemic administration, local delivery involves the
delivery of a single dose of the agent during PTCA.
Therefore, local delivery appears to be a potentially effective
method for the prevention of tissue response to injury.
Several agents have shown beneficial results in reducing
neointimal proliferation after PTCA in animal experiments.
Locally delivered ethanol (13), nitric oxide (10), vascular
endothelial growth factor (14) and antisense oligonucleo-
tides (15) have resulted in decreased neointimal prolifera-
tion after arterial injury. Two clinical trials have demon-
strated that local radiation therapy may have the potential to
reduce restenosis after PTCA (1,2).
17-Beta-estradiol and injury response. Previous experi-
ments in animals have demonstrated that estrogen admin-
istered subcutaneously for up to three weeks inhibited the
myointimal response to arterial injury (7,8). Recently, a
preliminary report has suggested that short-term subcuta-
neous estrogen therapy (6 to 17 days) may be effective in
reducing the injury response (16). Estrogen administered
intramuscularly for at least three weeks has also demon-
strated the potential to inhibit vascular SMC proliferation
and neointimal hyperplasia (17). However, the efficacy of
local delivery of BE to inhibit intimal hyperplasia has not
been previously studied.
In the present study, local delivery of BE was associated
with a markedly lower proliferative response compared with
the other two treatment groups. The neointimal area,
neointima/media area ratio, restenotic index and morpho-
logic percent stenosis were all significantly lower in the
BE-treated arterial segments. The decreased neointimal
hyperplasia after treatment with BE is probably due to the
inhibition of SMC proliferation. Assessment at different
time points could possibly provide additional information
on the effect of BE on SMC proliferation. Studies examin-
ing SMC proliferation after arterial injury have shown that
maximal SMC proliferative activity occurs during the first
seven days after experimental arterial injury and rapidly
decreases beyond seven days (18). We were able to demon-
strate significantly lower SMC proliferation at seven days in
the arterial segments treated with BE, compared with the
PTCA-only and vehicle-only treatment groups. The inhib-
itory effect of BE on SMC proliferation may be due to a
direct effect on SMC proliferation (19) or to enhanced
synthesis of nitric oxide by BE (20,21). Nitric oxide is
known to inhibit both SMC migration (22) and prolifera-
tion (23). The biologic effects of estrogen, like other steroid
hormones, involve intracellular receptors (24). Estrogen
receptors have been demonstrated in coronary arteries ob-
tained from autopsy specimens in both premenopausal and
postmenopausal women (25) and in cell cultures of human
saphenous vein and internal mammary artery specimens
(26). The beneficial effects of BE—the predominant circu-
lating estrogen in premenopausal women—on vascular
injury response may not be replicated by other kinds of
estrogens. For example, conjugated equine estrogen was
found to have no effect on neointimal proliferation in
nonhuman atherosclerotic primate models (27). In this
study, it is unlikely that loss of estrogen receptors in the
hypercholesterolemic monkeys could be responsible for the
lack of response to conjugated equine estrogen on neointi-
mal proliferation, as conjugated equine estrogen treatment
did result in a statistically significant decrease in atheroscle-
rotic plaque area and inhibited the progression of athero-
sclerosis (with no effect on neointimal proliferation) in the
same monkeys, thereby demonstrating responsiveness to
estrogen. Simultaneous administration of progesterone may
attenuate the vascular injury response to BE (28). A sexually
dimorphic response to estrogen has been reported after
arterial injury, with intact male rats deriving no benefit from
estrogen therapy (29). However, this sexually dimorphic
effect was not observed in another experiment with gona-
dectomized rats (8). In the present study, a significant effect
of BE on the neointimal proliferative response was noted in
both genders, although the male animals used in the study
had been castrated at birth.
Vehicle. 17-Beta-estradiol is a lipophilic compound with
poor solubility in aqueous solutions; therefore, it needs a
vehicle for parenteral administration. 2-Hydroxypropyl-
beta-cyclodextrin, a starch derivative, has been successfully
tested as an effective excipient for protein drugs (30). The
pharmacokinetics of HPCD are similar to that of insulin,
and the toxic dose (nephrotoxicity) has been estimated to be
200 mg/kg in rats (31). The dose of HPCD used to dissolve
BE in the present study was 0.63 mg/kg, far below the toxic
dose. Furthermore, HPCD has been used for administra-
tion of ophthalmic preparations and intravenous anesthetic
Table 3. Morphometric Data in Female Pigs
Characteristics BE
PTCA
Only
Vehicle
Alone p Value
Extent of injury 0.14 6 0.01 0.24 6 0.08 0.21 6 0.07 NS
Neointimal area (mm2) 0.25 6 0.07 0.73 6 0.3 1.51 6 1.05 NS
Neointima area/fracture length (mm2) 0.25 6 0.13 0.46 6 0.11 0.77 6 0.41 0.05
Neointima area/media area 0.33 6 0.07 1.23 6 0.43 1.99 6 1.16 NS
Restenotic index 1.37 6 0.2 2.75 6 0.38 2.93 6 0.43 ,0.05
Data are presented as the mean value 6 SEM.
Abbreviations as in Table 1.
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agents in humans (32,33). In the present study, the neoin-
timal response to injury was similar in HPCD-treated
arteries and arteries undergoing PTCA only. Therefore,
HPCD itself did not exert any significant influence on
neointimal proliferation.
Clinical evidence. Retrospective studies in humans have
shown no benefit of hormonal replacement therapy on
angiographic restenosis after PTCA (34), although one
study did show a beneficial effect after directional atherec-
tomy (35). However, conjugated estrogen (and not BE) was
the predominant form of estrogen used in many of these
patients, and no information on concomitant use of proges-
terone is available. In addition, it is not known whether
hormone replacement therapy could achieve a sufficient
concentration of estrogen locally at the PTCA site to exert
a significant response.
Study limitations. It is possible that spillover of BE into
the systemic circulation could occur during local delivery.
Also, tissue uptake and retention of BE after local delivery
were not measured. However, the results of the morpho-
metric and immunohistochemical analyses clearly demon-
strate a significant difference in the arteries treated with BE
compared with untreated vessels, which is highly suggestive
of an effect due to the locally delivered BE. The efficacy of
the InfusaSleeve catheter in delivering various agents intra-
murally has been reported in previous studies. At a support
balloon pressure similar to that used in the present study, a
sixfold higher concentration in the arterial wall was achieved
by local delivery, as compared with the arterial wall concen-
tration achieved by systemic administration (36). In another
study, persistent retention in the arterial wall of locally
delivered tissue factor pathway inhibitor was demonstrated
for at least 48 h after delivery (37). A strong argument
against a systemic effect due to spillover is that, in the
present model, where all three treatment arms were applied
in each animal, the systemic effects of BE (if any) due to
spillover would be expected to affect all three coronary
arteries in each animal equally, providing equal protection to
all vessels. The differences in the results between the arteries
treated with BE compared with PTCA only and vehicle
alone cannot therefore be attributed to such systemic effects.
Furthermore, BE that enters the circulation is rapidly
eliminated, mostly by the liver (38).
Conclusions. We have shown that a single dose of BE
delivered locally during PTCA in a porcine model has the
potential to decrease neointimal hyperplasia significantly,
probably by inhibition of SMC proliferation. Previous
studies have demonstrated that treatment with BE is asso-
ciated with inhibition of proliferation of human vascular
SMCs in cell culture assays (6). The local delivery of BE can
be performed safely with the InfusaSleeve catheter, without
risk of additional injury. The local administration of BE is
therefore a promising new approach that may be useful in
preventing the proliferative response after PTCA. Its use-
fulness in preventing restenosis after PTCA merits further
investigation.
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